Resumen | A 2-dose regimen of the BNT162b2 vaccine (Pfizer-BioNTech) against SARS-CoV-2 was authorized in December 2020 based on reported 94.8% efficacy.聽Although an association between vaccination and a reduction in symptomatic disease has been well described, an association with asymptomatic infection remains unclear. 聽 |
---|---|
Procedencia del autor |
Texto completo |
---|
Tipo de documento | |
---|---|
Especialidad(es) |
Publicado en el sitio | 2021-07-14 09:34:25 |
---|
(aún no hay comentarios disponibles para este recurso)
Comentarios